Services
CellCarta has extensive experience with various antisense oligonucleotide (ASO) technologies to modulate RNA expression, with over 10,000 ASO molecules screened to date.
We have proprietary knowledge to prioritize candidate therapeutic RNA targets in specific cell and disease types, built on our expertise in exploring the transcriptome. Our ASO analysis includes recommendations regarding the evaluation of ASO off-target effects before moving into clinical trials
Through our four unique modules, we provide expertise to support your ASO drug development pipeline.
Our team is internationally recognized for its expertise in the field of RNA and our workflow for ASO specificity analysis was recommended by the Oligonucleotide Safety Working Group in a publication: